Literature DB >> 22476470

The histological growth pattern of colorectal cancer liver metastases has prognostic value.

Gert G Van den Eynden1, Nigel C Bird, Ali W Majeed, Steven Van Laere, Luc Y Dirix, Peter B Vermeulen.   

Abstract

Little is known about the biological characteristics that determine the prognosis of colorectal cancer (CRC) liver metastases. In previous work we reported three different histological patterns of the tumour-liver interface of CRC liver metastases, termed the pushing, replacement and desmoplastic growth pattern (GP). The purpose of this study was to confirm differences in angiogenic and hypoxic properties of CRC liver metastases with different GPs in a large data set and to study the value of the GP as a prognostic factor. In 205 patients undergoing a resection of CRC liver metastases, the GP of the metastasis was determined using haematoxylin-eosin and Gordon Sweet's silver staining. The tumour cell proliferation fraction (TCP%), endothelial cell proliferation fraction (ECP%) and carbonic anhydrase 9 (CA9) expression were determined using immunohistochemistry. Standard clinicopathological data and overall survival were recorded. 27.8, 15.6, 34.6 and 17.6 % of liver metastases had a replacement, pushing, desmoplastic and mixed GP, respectively. Analyses of TCP%, ECP% and CA9 expression demonstrated that CRC liver metastases with a replacement GP are non-angiogenic, while the ones with a pushing GP are the most angiogenic with angiogenesis being, at least partially, hypoxia-driven. GP (pushing or not) was the only independent predictor of survival at 2 years. CRC liver metastases grow according to different GP patterns with different angiogenic properties. At 2 years of follow-up a GP with a pushing component was an independent predictor of poor survival, suggesting that the pushing GP is characterized by a more aggressive tumour biology. Further elucidation of the mechanisms and biological pathways involved in and responsible for the differences in GP between CRC liver metastases in different patients might lead to therapeutic agents and strategies taking advantage of this 2 year 'window of opportunity'.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476470     DOI: 10.1007/s10585-012-9469-1

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  22 in total

1.  Prognostic value of a biologic classification of non-small-cell lung cancer into the growth patterns along with other clinical, pathological and immunohistochemical factors.

Authors:  Peyman Sardari Nia; Eric Van Marck; Joost Weyler; Paul Van Schil
Journal:  Eur J Cardiothorac Surg       Date:  2010-05-07       Impact factor: 4.191

2.  Computed tomographic findings of colorectal liver metastases can be predictive for recurrence after hepatic resection.

Authors:  Junzo Yamaguchi; Ichiro Sakamoto; Toshio Fukuda; Hikaru Fujioka; Kou Komuta; Takashi Kanematsu
Journal:  Arch Surg       Date:  2002-11

3.  MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases.

Authors:  Martin Illemann; Nigel Bird; Ali Majeed; Maxwell Sehested; Ole D Laerum; Leif R Lund; Keld Danø; Boye Schnack Nielsen
Journal:  Mol Cancer Res       Date:  2006-05       Impact factor: 5.852

4.  Role of sinusoidal heparan sulfate proteoglycan in liver metastasis formation.

Authors:  J Tóvári; S Paku; E Rásó; G Pogány; I Kovalszky; A Ladányi; K Lapis; J Tímár
Journal:  Int J Cancer       Date:  1997-05-29       Impact factor: 7.396

Review 5.  Biology of colorectal liver metastases: A review.

Authors:  Nigel C Bird; David Mangnall; Ali W Majeed
Journal:  J Surg Oncol       Date:  2006-07-01       Impact factor: 3.454

6.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.

Authors:  S K Chia; C C Wykoff; P H Watson; C Han; R D Leek; J Pastorek; K C Gatter; P Ratcliffe; A L Harris
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

7.  Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.

Authors:  F Pezzella; U Pastorino; E Tagliabue; S Andreola; G Sozzi; G Gasparini; S Menard; K C Gatter; A L Harris; S Fox; M Buyse; S Pilotti; M Pierotti; F Rilke
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

8.  Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.

Authors:  Martin Illemann; Nigel Bird; Ali Majeed; Ole D Laerum; Leif R Lund; Keld Danø; Boye Schnack Nielsen
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396

9.  Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis.

Authors:  S Rasheed; A L Harris; P P Tekkis; H Turley; A Silver; P J McDonald; I C Talbot; R Glynne-Jones; J M A Northover; T Guenther
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

10.  Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia.

Authors:  F Stessels; G Van den Eynden; I Van der Auwera; R Salgado; E Van den Heuvel; A L Harris; D G Jackson; C G Colpaert; E A van Marck; L Y Dirix; P B Vermeulen
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

View more
  56 in total

1.  A Computational/Experimental Assessment of Antitumor Activity of Polymer Nanoassemblies for pH-Controlled Drug Delivery to Primary and Metastatic Tumors.

Authors:  Louis T Curtis; Piotr Rychahou; Younsoo Bae; Hermann B Frieboes
Journal:  Pharm Res       Date:  2016-06-29       Impact factor: 4.200

Review 2.  Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.

Authors:  Zowi R Huinen; Elisabeth J M Huijbers; Judy R van Beijnum; Patrycja Nowak-Sliwinska; Arjan W Griffioen
Journal:  Nat Rev Clin Oncol       Date:  2021-04-08       Impact factor: 66.675

3.  Growth pattern of colorectal liver metastasis as a marker of recurrence risk.

Authors:  R L Eefsen; P B Vermeulen; I J Christensen; O D Laerum; M B Mogensen; H C Rolff; G G Van den Eynden; G Høyer-Hansen; K Osterlind; B Vainer; M Illemann
Journal:  Clin Exp Metastasis       Date:  2015-03-31       Impact factor: 5.150

4.  Radiologic and Histopathologic Correlation of Different Growth Patterns of Metastatic Uveal Melanoma to the Liver.

Authors:  Albert Liao; Pardeep Mittal; David H Lawson; Jenny J Yang; Eszter Szalai; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2017-11-06       Impact factor: 12.079

Review 5.  Breast cancer liver metastasis: current and future treatment approaches.

Authors:  Narmeen S Rashid; Jacqueline M Grible; Charles V Clevenger; J Chuck Harrell
Journal:  Clin Exp Metastasis       Date:  2021-03-06       Impact factor: 5.150

Review 6.  Non-angiogenic tumours and their influence on cancer biology.

Authors:  Tom Donnem; Andrew R Reynolds; Elizabeth A Kuczynski; Kevin Gatter; Peter B Vermeulen; Robert S Kerbel; Adrian L Harris; Francesco Pezzella
Journal:  Nat Rev Cancer       Date:  2018-03-09       Impact factor: 60.716

7.  Hypofractionated radiotherapy with tomotherapy for patients with hepatic oligometastases: retrospective analysis of two institutions.

Authors:  Jong Hoon Lee; Joo Hwan Lee; Hong Seok Jang; Hyo Chun Lee; Jung Won Lee; Dae Gyu Kang; Byoung Yong Shim; Bong-Hyeon Kye; Hyung Jin Kim; Hyeon-Min Cho; Young Jin Suh; Sung Hwan Kim
Journal:  Clin Exp Metastasis       Date:  2013-02-06       Impact factor: 5.150

8.  mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy.

Authors:  E P van der Stok; M Smid; A M Sieuwerts; P B Vermeulen; S Sleijfer; N Ayez; D J Grünhagen; J W M Martens; C Verhoef
Journal:  Mol Oncol       Date:  2016-09-20       Impact factor: 6.603

Review 9.  VEGF levels and the angiogenic potential of the microenvironment can affect surgical strategy for colorectal liver metastasis.

Authors:  Clarisse Eveno; Marc Pocard
Journal:  Cell Adh Migr       Date:  2012-11-01       Impact factor: 3.405

10.  Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.

Authors:  Laurent Dercle; Lin Lu; Lawrence H Schwartz; Min Qian; Sabine Tejpar; Peter Eggleton; Binsheng Zhao; Hubert Piessevaux
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.